What is HC Wainwright’s Forecast for SLNO FY2025 Earnings?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities researchers at HC Wainwright lifted their FY2025 EPS estimates for Soleno Therapeutics in a research note issued to investors on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.42 for the year, up from their previous estimate of $0.10. HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q4 2025 earnings at $0.83 EPS, Q1 2026 earnings at $0.88 EPS and FY2026 earnings at $4.82 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.39. The company had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million.

Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded Soleno Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Zacks Research upgraded shares of Soleno Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $114.00 price target (up previously from $106.00) on shares of Soleno Therapeutics in a report on Tuesday. Finally, The Goldman Sachs Group set a $125.00 price target on shares of Soleno Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $110.62.

Soleno Therapeutics Price Performance

Shares of NASDAQ SLNO opened at $43.75 on Thursday. The business has a fifty day moving average price of $47.25 and a two-hundred day moving average price of $61.57. The stock has a market capitalization of $2.35 billion, a PE ratio of -23.78 and a beta of -3.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88. Soleno Therapeutics has a fifty-two week low of $39.43 and a fifty-two week high of $90.32.

Institutional Trading of Soleno Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its holdings in shares of Soleno Therapeutics by 272.3% during the third quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock worth $156,298,000 after buying an additional 1,691,057 shares in the last quarter. Braidwell LP bought a new stake in Soleno Therapeutics during the 3rd quarter worth $86,662,000. Invesco Ltd. increased its holdings in Soleno Therapeutics by 132.3% in the 3rd quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock worth $101,435,000 after purchasing an additional 854,551 shares in the last quarter. Commodore Capital LP increased its holdings in Soleno Therapeutics by 121.3% in the 3rd quarter. Commodore Capital LP now owns 1,350,000 shares of the company’s stock worth $91,260,000 after purchasing an additional 740,000 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Soleno Therapeutics by 348.4% in the third quarter. Franklin Resources Inc. now owns 835,751 shares of the company’s stock valued at $56,497,000 after purchasing an additional 649,349 shares during the last quarter. Institutional investors and hedge funds own 97.42% of the company’s stock.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised EPS forecasts across 2025–2026 (Q4‑2025, Q1‑2026, full‑year 2025 and 2026 and quarterly 2026 guidance) and reiterated a “Buy” rating with a $120 price target — the firm now models FY2026 EPS of $4.82, up sharply from prior estimates, signaling an expectation of rapid revenue/profit growth that supports higher valuation. HC Wainwright raises estimates (MarketBeat)
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and set a $123 price target after citing that Soleno’s Vykat has captured roughly 12.5% market share in Prader‑Willi Syndrome — market‑share gains for a specialty orphan drug are a clear revenue catalyst and justify higher forward multiples. Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside
• Neutral Sentiment: Despite these upgrades, consensus estimates still show a negative EPS for the current fiscal year (consensus ~‑$3.72); analysts’ upgrades reflect rapid expected improvement but also introduce execution risk—stock performance will depend on continued uptake of Vykat and whether results match the newly raised projections. SLNO company page (MarketBeat)

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.